islet of Langerhans, haemalum-eosin stain (Photo credit: Wikipedia)
Researchers at Lund University have unexpectedly discovered that an old cancer drug can be used to prevent rejection of transplanted tissue.
The researchers now have high hopes that their discovery could lead to new treatments for both transplant patients and patients with autoimmune diseases.
The researchers behind the study, which has been published in the scientific journal PLOS ONE, work at the Rausing Laboratory, Lund University, where they have conducted research on brain tumours over many years.
“Our group were studying the effects of the old tumour drug Zebularine, developed in the USA in the 1960s, and by chance we discovered that it had completely unexpected effects on the immune system”, says Leif Salford, Senior Professor of Neurosurgery.
“It turned out that Zebularine has the ability to subdue the reaction of the body’s immune system. This could be important in situations where tissue or organs are transplanted. We also think it could be used to curb the body’s attacks on its own tissue in autoimmune diseases, for instance type 1 diabetes or rheumatoid arthritis”, says Dr Nittby.
In studies on animals, the researchers used rats that were made diabetic. The researchers transplanted the islets of Langerhans – cell groups in the pancreas producing insulin – from healthy rats from another kind of rat into those with diabetes. The diabetic rats were divided into two groups; one group were treated with Zebularine and the other, the control group, did not receive any treatment. The diabetic rats that were treated with Zebularine survived for a significantly longer period than the untreated rats.
“It is very interesting that we only treated them with Zebularine for two weeks, but the effects of the treatment could be observed throughout the 90-day follow-up period.
“The findings are very exciting and are a sign that the immune system was not just generally suppressed, but that the treatment was more targeted. Neither did we see any signs of side-effects”, said Dr Nittby.
The researchers are now working intensively to further refine the treatment. The next step is to teach certain cells in the immune system – the dendritic cells – to accept certain specific proteins using the Zebularine treatment.
This would mean that the treatment could be targeted even more.
“If we succeed with that, we believe it could be of clinical significance both to prevent rejection of transplanted organs and to stop the body attacking its own tissue in autoimmune diseases.
The Latest Bing News on:
Zebularine
- Epigenetic-dependent Regulation of Drug Transport and Metabolismon February 22, 2021 at 4:00 pm
†Indirect regulation by targeting 3'-UTR of PXR. ‡Potentially direct targeting of 3'-UTR and indirect by targeting 3'-UTR of VDR. Research in the authors' laboratory is supported by grants ...
- Barrett's Esophagus: Can Biomarkers Predict Progression to Malignancy?on February 14, 2021 at 4:00 pm
It was demonstrated, in vitro and in vivo, that re-expression of epigenetically silenced tumor-suppressor genes is possible by using demethylating (e.g., 5´-AZA and Zebularine) and histone ...
The Latest Google Headlines on:
Zebularine
The Latest Bing News on:
Preventing rejection of transplanted tissue
- Immunosuppressants market is anticipated to grow at a CAGR of around 14% in terms of revenue during the forecast period 2020 - 2027on February 23, 2021 at 10:33 pm
The global immunosuppressants market is expected to reach the market value of around US$ 45,000 Mn by 2027 and is anticipated to grow at a CAGR of around 14% in terms of revenue during the forecast ...
- New hope for kidney transplant patientson February 21, 2021 at 4:00 pm
he persuaded the drug company Wyeth to redirect its research into the drug's use in preventing kidney rejection. Robert Johnson, one of Britain's leading transplant surgeons at Manchester Royal ...
- Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz®on February 17, 2021 at 8:15 pm
Inc. announced today filing of a patent application covering the use of ImmCelz® regenerative cell therapy for preventing rejection of transplanted organs. ImmCelz® is a cellular therapy that ...
- Creative medical Technology Holdings files patent to prevent organ transplant rejection using ImmCelz®on February 16, 2021 at 5:00 am
Creative medical Technology Holdings files patent to prevent organ transplant rejection using ImmCelz® PHOENIX, Feb. 16, 2021 / ...
- Organ transplant recipients can develop immunity after COVID-19, despite immunosuppressionon February 10, 2021 at 5:42 am
"We followed 18 transplant recipients who were taking immunosuppressive medications to prevent rejection and who developed ... two lung and one composite tissue allograft (composed of different ...
- Story tips from Johns Hopkins experts on Covid-19on February 9, 2021 at 11:06 am
"We followed 18 transplant recipients who were taking immunosuppressive medications to prevent rejection and who developed ... two lung and one composite tissue allograft (composed of different ...
- Chronic Rejection: A Significant Role for Th17-mediated Autoimmune Responses to Self-antigenson January 7, 2021 at 4:00 pm
Donor-specific alloimmune responses both pretransplant and de novodevelopment post-transplant are important risk factors for chronic rejection. Autoimmune responses to tissue-restricted self ...
- New technique can reduce heart transplant rejectionon July 30, 2020 at 2:40 pm
Currently when patients receive a transplant, they need lifelong immunosuppression to prevent their own immune system ... immune cells which we know drive acute rejection. It also improves the state ...
- Islet Cell Transplantation for the Treatment of Diabeteson January 8, 2014 at 10:24 am
This attack on the donor tissue is called "rejection." All transplant recipients must take, for the rest of their life, strong drugs to suppress the immune response and prevent rejection.
